Upload File

a smart spin on the science of cell processing. · or approval by the u.s. food and drug...

  • Home
  • Documents
  • A SMART SPIN ON THE SCIENCE OF CELL PROCESSING. · or approval by the U.S. Food and Drug Administration (FDA), European ... * Depending on cell type, cell concentration and source
2
Lovo Cell processing system A SMART SPIN ON THE SCIENCE OF CELL PROCESSING. For laboratory use only

Upload: vanliem

Post on 05-May-2018

213 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: A SMART SPIN ON THE SCIENCE OF CELL PROCESSING. · or approval by the U.S. Food and Drug Administration (FDA), European ... * Depending on cell type, cell concentration and source

LovoCell processing system

A SMART SPIN ON THE SCIENCE OF CELL PROCESSING.

For laboratory use only

Page 2: A SMART SPIN ON THE SCIENCE OF CELL PROCESSING. · or approval by the U.S. Food and Drug Administration (FDA), European ... * Depending on cell type, cell concentration and source

A smart spin is soft cell processing Enabling quality care depends on preserving the quality of your cell product. Lovo’s proprietary spinning membrane filtration technology gently washes and separates white blood cells, maintaining their viability by avoiding unnecessary pelletization. With single-use disposable sets and few points of direct operator interaction, Lovo can reduce the risk of sample contamination.

A smart spin is swift cell recovery Improving procedural efficiency should never compromise quality. The only automated processing platform with a spinning membrane and intelligent autodilution, Lovo removes supernatant swiftly and safely, increasing the speed and accuracy of mononuclear cell recovery while minimizing cell loss.

© 2014 Fresenius Kabi USA | #2897

Lovo proprietary spinning membrane

A smart spin is single-platform design Gone are the days of ad hoc cell processing. A small, convenient bench-top instrument, Lovo streamlines cell washing and concentration into a single platform that’s easy to incorporate into your laboratory’s workflow. Lovo automates the labor-intensive tasks of supernatant exchange, volume reduction and volume addition of white blood cell products, offering operator-defined processing parameters that allow for improved flexibility, control and results specific to your cell processing needs.

Case

Membrane

Supernatant channels

Supernatant output port

Star drive

Cell source input port

Rotor

Rotation

Concentrated cell output port

99% supernatant reduction in under 7 minutes in a 200 mL source product1

Get your lab moving on the path to smooth, simple cell processing. Call 1 800 333 6925 or visit www.fresenius-kabi.us

Fresenius Kabi considers the Lovo system for laboratory use and not subject to medical device registration, clearance, or approval by the U.S. Food and Drug Administration (FDA), European Union, Health Canada, or the Australian Therapeutics Goods Administration. Cells processed on this system that are intended for diagnostic purposes, for direct transfusion, or for use in the production of a therapeutic product(s) or vaccine(s) for clinical use may require advance regulatory clearance or approval, which is the sole responsibility of the user. 1 Presented at the 19th Annual International Society for Cell Therapies Meeting, April 2013. Data collected using prototype instrument. Wegener C, Heber C, Min K (2013). Novel Cell

Washing Device Using Spinning Membrane Filtration. Cytotherapy. 15(4) S27. Abstract 86.

Instrument features

Processing volume range Source: 100 mL – <8 L

Output:

50 mL – 5 L*

Intelligent auto dilution for packed cell volumes

PCV >3%

Benchtop design Height: 24” Width: 34” Depth: 18” Weight: 75 lbs

Wash out range: Up to 99.999%*

* Depending on cell type, cell concentration and source volume.

WBC RBC PLT SUPERNATANT

20

0

40

60

80

92.3%

74.4%

14.2%

1.3%

100

Mean spinning membrane post-wash recoveries of fresh PBMC (n=22)1


Regulation of Cell & Gene Therapy Products for Clinical Trials · Tissue-Based Products • FDA: Regulates Cell & Gene Therapies in the USA ... clinical laboratory studies to support

Desirable cytolytic immune effector cell recruitment by ... Success of dendritic cell (DC) therapy in treating malignancies is depending on the DC capacity to attract immune effector

Food & Beverage Industry Brochure - daemar.com · applications including: FDA Silcone, FDA EPDM, FDA NBR, FDA Neoprene, FDA FKM (Viton), FDA PTFE, FDA PTFE Encapsulated, FFKM (Kalrez)

THE EMERGENCY GUIDE TO FDA WARNING …€¦ · The Emergenc Gide to FDA Warning Letters & FDA 483 The FDA Grop.com 1 THE EMERGENCY GUIDE TO FDA WARNING LETTERS & FDA 483 …

FDA IND Review: Regulations and Challenges Wilson W. Bryan, M.D. FDA / CBER / OCTGT [email protected] Workshop on Cell and Gene Therapy Clinical

FDA greenlights novel stem cell therapy...01. FDA greenlights novel stem cell therapy 02. Events calendar 03. Message from the Chair 04. Patients give thanks 05. Glaucoma specialist

FDA PEER REVIEW GUIDE FOR THE EVALUATION OFnteu282.com/announce/110516d07.pdf · statisticians, and mechanical, electronics, materials, and biomedical engineers. Depending on the

FDA 2013 Clinical Investigator Training Course Preparing an IND Application: Preclinical Considerations for Cell and Gene Therapy Products

Transport Across the Cell Membrane - Ms. Murray's Biology · Transport Across Membranes •The cell decides how things will move across the membrane depending on the concentration

Overview of FDA Perspective on the Ethics of Stem Cell Therapy

REGULATORY SCIENCE FDA Oversight of Cell …...phase 1 drugs from complying fully with the cGMP regulations. In an accompanying guidance (6), FDA provides recommenda-tions on approaches

FDA Regulation of Cell Therapies for Autoimmune Diseases · FDA Regulation of Cell Therapies for Autoimmune Diseases Autoimmune Diseases Coordinating Committee (ADCC) October 17,

FDA Perspective on the Regulation of TCR/CAR T … · FDA Perspective on the Regulation of TCR/CAR T-cell Products . Raj K. Puri, M.D., Ph.D. Director, Division of Cellular and Gene

FDA - CAT002.E3 _ FDA 800_900

How to Conduct Market Diligence for Cell Therapy Safety ......Cell therapy is a rapidly growing market, with the FDA expecting 200 new INDs and 10-20 approvals of cell and gene therapy

Mitosis and Protein Synthesis. Cell Division Occurs in humans and other organisms at different times in their life. Cell Division differs depending on

AVOID AN FDA WARNING LETTER - HBW Insight · Hollywood Skincare and Crescent Health Center were hit with FDA warning letters in 2016 for claims on their DermaSet Stem Cell 3D Renewal

FDA Perspective on Commercial Facility Design for Cell and

FDA Oral History Interviews, FDA retired scientists

Current US FDA Regulation of Cell Therapy US FDA... · Current US FDA Regulation of Cell Therapy Andra Miller, Ph.D. ... device or biologic product ... 4.Primary function in recipient

FDA Oversight of Cell Therapy Clinical Trials Celia Witten, Ph.D., M.D. Office Director, Office of Cellular, Tissue, and Gene Therapies CBER/FDA ISSCR/CIRM/ISCT

Cell Cycle and Mitosis. Cell Cycle Only a Eukaryotic Process Unicellular: asexual reproduction Multicellular: growth and repair Rate may differ depending

1 Regulatory Implications of Neoplastic Cell Substrate Tumorigenicity Andrew M. Lewis Jr. M.D. DVP, OVRR, CBER, FDA

3D cell culture protocol | SeedEZ Coatings for Specific Cell … ·  · 2013-10-13PROTOCOL: 3D culture of osteoblastic cells ... depending on cell type, other animal-derived or synthetic

Bioanalytical Method Validation - FDA - U S Food · PDF fileBioanalytical Method Validation ... 36 recommendations can be modified depending on the specific type of analytical method

EnhancingAntibodyFcHeterodimerFormationthrough ... · human embryonic kidney cell line 293 using LipofectamineTM 2000 reagent (Invitrogen) or polyethylenimine depending on the volume

Universal Computation in Simple One-Dimensional Cellular ... · cellular automata with seven states per cell for a transition function depending on the cell itself and its nearest

Regulatory Starting Materials— An FDA Perspective · PDF filesynthetic process in a marketing application –One or more starting materials possible depending on linear or convergent

FDA Presentation FDA Presentation

Ancillary Materials for Cell and Tissue-Based Products · Ancillary Materials for Cell and Tissue-Based Products Elizabeth Read, MD Expert Committee Member ... • FDA first used

CCiirrccuullaattoorryy SSyysstteemm · heart attack leads to cell damage, which may be permanent and lead to cell necrosis (death), depending on the severity of the attack and the

THE EMERGENCY GUIDE TO FDA WARNING LETTERS & FDA 483 · 2018-12-13 · The Emergenc Gide to FDA Warning Letters & FDA 483 The FDAGrop.com 4 FDA 483 RESOLVING FDA 483 OBSERVATIONS

FDA Perspective on the Ethics of Stem Cell Therapy · PDF fileOverview of FDA Perspective on the Ethics of Stem Cell Therapy Robert M. Nelson, M.D., Ph.D. Pediatric Ethicist, Office

Silencing the Elusive Sézary cell Past, Present, & · PDF fileSilencing the Elusive Sézary cell Past, Present, & Future ... a proposal of the ... (PTCL) FDA Approved Therapies

CELLS EXCHANGE MATERIALS · removed from the cell. Different cells have different requirements and different products, depending on the particular role of the cell. There are, however,